# Table of Contents

Preface ........................................................................................................... V

**Part I: The Chemical Industry in China ................................................. 1**

1 The Global Chemical Industry ................................................................. 3
   Gunter Festel
   1.1 Some Basic Facts About the Chemical Industry ............................ 3
   1.2 Transformation of the Chemical Industry ..................................... 4
   1.3 Impact of Industrial Biotechnology ................................................... 7

2 The Petrochemical Industry in China ....................................................... 9
   Jörg Wuttke
   2.1 Major Players in the Chinese Chemical Industry ......................... 9
   2.2 Underpinning Economic Growth and the Energy Bottleneck .......... 10
   2.3 Outlook for Feedstock Supply ....................................................... 13
   2.4 Cracker Capacity Development ..................................................... 14
   2.5 Consumption of Ethylene and its Derivatives ............................... 15
   2.6 WTO Entry and Its Impact on China's Petrochemical Industry ....... 18
   2.7 Competitive Environment in the Chinese Market ....................... 19
   2.8 Summary and Outlook ................................................................. 22

3 Activities of European Chemical Companies in China ......................... 23
   Heinz Mueller
   3.1 Executive Summary ....................................................................... 23
   3.2 Activities in China ......................................................................... 24
   3.3 Investment in China ....................................................................... 27
   3.4 Focus on Subsegments .................................................................. 30
   3.5 Effects of Investment and Positioning on Sales ............................. 37
   3.6 Selected Chemical Companies in China ....................................... 39

4 Research and Development in China ...................................................... 47
   Gunter Festel, Harald Pielartzik and Martin S. Völlmer
   4.1 Scope and Structure of R&D in China ........................................... 47
   4.2 R&D by Foreign Chemical and Pharmaceutical Companies .......... 50
   4.3 Conclusion and Outlook ............................................................... 52

5 Chemical Industry Parks in China .......................................................... 53
   Gunter Festel and Yong Geng
   5.1 Industrial Parks and Their Infrastructures ..................................... 53
VIII Table of Contents

5.2 Site Selection Criteria .......................................................... 55
5.3 Important Aspects for Foreign Investors .................................... 57
5.4 Selected Chemical Industry Parks in China ............................... 59

6 Trends in the Chinese Fine Chemicals Market – Opportunities and
Threats for the European Fine Chemicals Industry ....................... 63
Dahai Yu

6.1 General Introduction to the Fine Chemicals Market .................. 63
6.2 The Chinese Fine Chemicals Industry and Recent Developments ... 65
6.3 Scenarios for Future Developments ........................................ 69
6.4 Opportunities and Threats to the European Fine Chemicals Industry... 70
6.5 Conclusion ............................................................................. 71

7 Chemicals for China’s Chip Industry ......................................... 73
Klaus Griesar

7.1 The Semiconductor Industry – Market Growth ................. 73
7.2 Technological Innovation in the Microchip Industry .............. 74
7.3 Electronics Chemicals and Semiconductor Manufacturing ....... 75
7.4 Semiconductor Industry to Get Boost in China ..................... 80
7.5 China Promises Great Potential, but Plenty of Pitfalls ............ 84
7.6 Electronics Chemicals in China ............................................. 85

Part II: The Pharmaceutical Industry in China .......................... 89

8 China’s Pharmaceutical Market: Business Environment and
Market Dynamics ....................................................................... 91
Michael Brueckner, Marc P. Philipp and Joachim E. A. Luithle

8.1 Introduction ............................................................................ 91
8.2 Business Environment for the Pharmaceutical Industry in China .... 92
8.3 Market Characteristics and Dynamics of China’s
Pharmaceutical Industry .......................................................... 95
8.4 Conclusion and Outlook ....................................................... 107

9 Developing the Pharmaceutical Business in China – The Case
of Novartis ................................................................................ 109
Angela Wang and Maximilian von Zedtwitz

9.1 Changing Pharmaceutical Environment in China ................. 109
9.2 Novartis Pharma in China ................................................... 110
9.3 Strategic vs. Potential Regions in China ................................. 112
9.4 Analyzing the Pharmaceutical Business Environment ............ 114
9.5 Conclusion .......................................................................... 119
Table of Contents

10 China’s Approach to Innovative Pharmaceutical R&D: A Review .......................... 121
   David E. Webber
   10.1 Chinese Pharmaceutical R&D – Current Status ........................................... 121
   10.2 Government Agencies Driving Biopharmaceutical R&D ............................ 124
   10.3 Factors Important in Country Competitiveness in Pharmaceutical R&D ........ 126
   10.4 Collaboration with the Multinational Pharmaceutical Companies ............... 129
   10.5 Conclusion .................................................................................................... 131

11 Foreign Direct Investment by Multinational Corporations in China – The Pharmaceutical Sector ............................................. 133
   Xiangdong Chen and Guido Reger
   11.1 Introduction .................................................................................................... 133
   11.2 Foreign Direct Investment (FDI) in the Pharmaceutical Sector in China: Trends and Structures ....................................................... 133
   11.3 Technology, Patents and Foreign Direct Investment in China by Multinational Pharmaceutical Companies ....................................... 143
   11.4 Conclusions .................................................................................................... 146

12 Competing in the Chinese Antibiotics Market – Cephalosporins 1982-2000 .......................................................... 149
   Gail E. Henderson and William A. Fischer
   12.1 Cephalosporins and China ........................................................................... 149
   12.2 The Business of Antibiotics in China, Early 1980s .................................... 150
   12.3 Market Changes from the Mid-1980s ......................................................... 151
   12.4 Characteristics of the Chinese Market for Cephalosporins:
       Late 1990s ........................................................................................................ 153

Part III: The Experience of Successful European Companies in China .................................................. 157

13 Swimming Ahead of the Shoal – The History of BASF in Greater China ......................... 159
   Andreas Kreimeyer
   13.1 The Founding of BASF ................................................................................. 159
   13.2 A Partnership Sealed by Colors .................................................................. 160
   13.3 The Two World Wars .................................................................................. 161
   13.4 The Postwar Era ......................................................................................... 161
   13.5 Towards the Future ..................................................................................... 167
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Establishing a Competitive Production Network in Asia</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td>Otto Kumberger</td>
<td></td>
</tr>
<tr>
<td>14.1</td>
<td>Asia – Shaping the Future of the Chemical Industry</td>
<td>171</td>
</tr>
<tr>
<td>14.2</td>
<td>BASF’s Production Philosophy</td>
<td>172</td>
</tr>
<tr>
<td>14.3</td>
<td>Using BASF’s Verbund Concept to Shape New Sites in Asia</td>
<td>172</td>
</tr>
<tr>
<td>14.4</td>
<td>BASF’s Investments in Asia-Pacific</td>
<td>174</td>
</tr>
<tr>
<td>14.5</td>
<td>Cultivating the Best Team in Asia-Pacific</td>
<td>179</td>
</tr>
<tr>
<td>15</td>
<td>Bayer – A Multinational Committed to China</td>
<td>181</td>
</tr>
<tr>
<td></td>
<td>Elmar Stachels</td>
<td></td>
</tr>
<tr>
<td>15.1</td>
<td>Bayer in China</td>
<td>181</td>
</tr>
<tr>
<td>15.2</td>
<td>Bayer’s Core Competencies</td>
<td>182</td>
</tr>
<tr>
<td>15.3</td>
<td>A Strategy for Growth</td>
<td>185</td>
</tr>
<tr>
<td>15.4</td>
<td>Summary and Outlook</td>
<td>187</td>
</tr>
<tr>
<td>16</td>
<td>Bicell – The First Sino-German Biotechnology Company</td>
<td>189</td>
</tr>
<tr>
<td></td>
<td>Kai Lamottke, Nicole Feling and Christian Haug</td>
<td></td>
</tr>
<tr>
<td>16.1</td>
<td>Considerations for a Chinese Site</td>
<td>189</td>
</tr>
<tr>
<td>16.2</td>
<td>Starting from Scratch in Shanghai</td>
<td>193</td>
</tr>
<tr>
<td>16.3</td>
<td>Outlook</td>
<td>197</td>
</tr>
<tr>
<td>17</td>
<td>Ciba Specialty Chemicals in China – Global Direction and Local Expertise</td>
<td>199</td>
</tr>
<tr>
<td></td>
<td>Kuno Kohler</td>
<td></td>
</tr>
<tr>
<td>17.1</td>
<td>History</td>
<td>199</td>
</tr>
<tr>
<td>17.2</td>
<td>Industries We Serve</td>
<td>200</td>
</tr>
<tr>
<td>17.3</td>
<td>Business Environment</td>
<td>204</td>
</tr>
<tr>
<td>17.4</td>
<td>Strategic Priorities</td>
<td>206</td>
</tr>
<tr>
<td>17.5</td>
<td>Future Development</td>
<td>209</td>
</tr>
<tr>
<td>18</td>
<td>Degussa: Transforming the China Region</td>
<td>211</td>
</tr>
<tr>
<td></td>
<td>Eric Baden</td>
<td></td>
</tr>
<tr>
<td>18.1</td>
<td>Early Mover</td>
<td>211</td>
</tr>
<tr>
<td>18.2</td>
<td>Why China, Why Now?</td>
<td>211</td>
</tr>
<tr>
<td>18.3</td>
<td>The Holding Company – Dinosaur or Dragon?</td>
<td>214</td>
</tr>
<tr>
<td>18.4</td>
<td>As Decentralized as Possible – As Centralized as Necessary</td>
<td>216</td>
</tr>
<tr>
<td>18.5</td>
<td>Sourcing China – A Profitable Growth Market</td>
<td>216</td>
</tr>
<tr>
<td>18.6</td>
<td>Growth</td>
<td>217</td>
</tr>
<tr>
<td>18.7</td>
<td>The Other Side of the Medal</td>
<td>219</td>
</tr>
<tr>
<td>18.8</td>
<td>Conclusion</td>
<td>220</td>
</tr>
</tbody>
</table>
19 A Toolbox for China – Lessons from the China Experience of Degussa Construction Chemicals ........................................ 221
Boris Gorella and Christian Kober

19.1 Riding the Swift Juggernaut ........................................ 221
19.2 Five Key Issues Facing Foreign Businesses in China ........... 225
19.3 The Road Ahead .................................................. 245
19.4 The Take-Away .................................................. 245

20 DSM in China: In Touch with Evolving Needs in the Specialty Chemicals Market ........................................ 247
Stefan Sommer

20.1 Introduction ...................................................... 247
20.2 Royal DSM – From Coal to Biotechnology ...................... 247
20.3 The Early Years of DSM in China ................................ 251
20.4 The 1990s and the New Millennium ............................ 252
20.5 DSM and China in the Asian Century ........................... 259
20.6 China and DSM – Managing the Future ....................... 260
20.7 Conclusion ...................................................... 263

21 Vitamins – Opportunities and Challenges for Both Western and Chinese Producers ........................................ 265
Manfred Eggersdorfer

21.1 Vitamins Are a Dynamic Market .................................. 265
21.2 Vitamins Require a Complex Production Set-Up ............... 266
21.3 New Entrants Result in a Competitive Environment .......... 266
21.4 New Breakthrough Technologies Impact Competitive Position .... 269
21.5 Product Forms Are an Additional Differentiator ............... 270
21.6 Summary and Outlook .......................................... 272

Authors ........................................................................... 273

Literature ........................................................................ 287

Index ............................................................................. 291
The Chemical and Pharmaceutical Industry in China
Opportunities and Threats for Foreign Companies
Festel, G.; Kreimeyer, A.; Oels, U.; von Zedtwitz, M.
(Eds.)
2005, XII, 296 p., Hardcover
ISBN: 978-3-540-22544-7